Trial · NCT02699749
Results by group221
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 221
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule A: TAK-931 30 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule A: TAK-931 40 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule A: TAK-931 50 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule A: TAK-931 60 mg | 2 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule B: TAK-931 60 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule B: TAK-931 80 mg | 2 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule B: TAK-931 100 mg | 1 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule B: TAK-931 120 mg | 1 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule D: TAK-931 20 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule D: TAK-931 30 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule D: TAK-931 40 mg | 1 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule E: TAK-931 100 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule E: TAK-931 120 mg | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03 | Schedule E: TAK-931 150 mg | 2 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule A: TAK-931 30 mg | 3 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule A: TAK-931 40 mg | 3 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule A: TAK-931 50 mg | 16 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule A: TAK-931 60 mg | 3 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule B: TAK-931 60 mg | 3 | Participants | ||
| Number of Participants With Reporting One or More Treatment-emergent Adverse Events (TEAEs) | Schedule B: TAK-931 80 mg | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02699749/results